Literature DB >> 12374640

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine.

K Ito1, K Yoshida, K Sato, H Takahashi, M Kamata, H Higuchi, T Shimizu, K Itoh, K Inoue, T Tezuka, T Suzuki, T Ohkubo, K Sugawara, K Otani.   

Abstract

A variable number of tandem repeats (VNTR) in the second intron of the serotonin transporter gene (STin2) has been studied in association with the susceptibility to affective disorders. Recently, it was reported that selective serotonin reuptake inhibitors were more effective in patients with major depressive disorder having the homozygous allele pair (12-copy/12-copy) of VNTR in the STin2 than in ones having other allele combinations. As the study had methodological problems, further studies are needed to confirm the above finding. Therefore, the authors investigated whether the allelic variation of VNTR in the STin2 was associated with the antidepressant response to fluvoxamine in 66 patients with major depressive disorder. Fluvoxamine was prescribed up to 200 mg/day in the dosing protocol for 6 weeks. The present study showed no significant association between the polymorphism of VNTR in the STin2 and the treatment response to fluvoxamine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374640     DOI: 10.1016/s0165-1781(02)00141-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  15 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  [Monoaminergic function in major depression. A possibly helpful tool for choosing treatment strategy].

Authors:  O Moeller; C Norra; G Gründer
Journal:  Nervenarzt       Date:  2006-07       Impact factor: 1.214

Review 3.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 4.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

5.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Authors:  Gisa Gerstenberg; Toshiaki Aoshima; Takashi Fukasawa; Keizo Yoshida; Hitoshi Takahashi; Hisashi Higuchi; Yoshiko Murata; Ritsuko Shimoyama; Tadashi Ohkubo; Tetsuo Shimizu; Koichi Otani
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

6.  The association between serotonin transporter gene promotor polymorphism (5-HTTLPR) and elemental mercury exposure on mood and behavior in humans.

Authors:  Diana Echeverria; James S Woods; Nicholas J Heyer; Michael D Martin; Dianne S Rohlman; Federico M Farin; Tingting Li
Journal:  J Toxicol Environ Health A       Date:  2010

Review 7.  From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes.

Authors:  Alessandro Serretti; Paola Artioli
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

Review 8.  Milnacipran versus other antidepressive agents for depression.

Authors:  Atsuo Nakagawa; Norio Watanabe; Ichiro M Omori; Corrado Barbui; Andrea Cipriani; Hugh McGuire; Rachel Churchill; Toshi A Furukawa
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

Review 9.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

10.  Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression.

Authors:  Hisashi Higuchi; Hitoshi Takahashi; Mitsuhiro Kamata; Keizo Yoshida
Journal:  Neuropsychiatr Dis Treat       Date:  2009       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.